New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis

Justin O'Grady; Markus Maeurer; Peter Mwaba; Nathan Kapata; Matthew Bates; Michael Hoelscher; Alimuddin Zumla

doi:10.1097/MCP.0b013e3283452346

New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis

Justin O'Grady
, Markus Maeurer
, Peter Mwaba
, Nathan Kapata
, Matthew Bates
, Michael Hoelscher
, Alimuddin Zumla

Norwich Medical School

Research output: Contribution to journal › Literature review › peer-review

73 Citations (Scopus)

22 Downloads (Pure)

Abstract

In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and discuss future prospects for TB diagnostics. Current technologies for the detection of drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the ‘holy grail’ diagnostic for TB must fulfil all technical specifications for a good point-of-care test, screen for drug resistance concurrently and be adaptable to the various health system levels and to countries with diverse economic status and TB burden.

Original language	English
Pages (from-to)	134-141
Number of pages	8
Journal	Current Opinion in Pulmonary Medicine
Volume	17
Issue number	3
DOIs	https://doi.org/10.1097/MCP.0b013e3283452346
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/MCP.0b013e3283452346

COPM_drug_resistant_TB_review_2011.pdfFinal published version, 300 KB

Cite this

@article{bcb0ffa5dfbd4e799244e907bf0efb91,

title = "New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis",

abstract = "In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and discuss future prospects for TB diagnostics. Current technologies for the detection of drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the {\textquoteleft}holy grail{\textquoteright} diagnostic for TB must fulfil all technical specifications for a good point-of-care test, screen for drug resistance concurrently and be adaptable to the various health system levels and to countries with diverse economic status and TB burden.",

author = "Justin O'Grady and Markus Maeurer and Peter Mwaba and Nathan Kapata and Matthew Bates and Michael Hoelscher and Alimuddin Zumla",

year = "2011",

doi = "10.1097/MCP.0b013e3283452346",

language = "English",

volume = "17",

pages = "134--141",

journal = "Current Opinion in Pulmonary Medicine",

issn = "1070-5287",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis

AU - O'Grady, Justin

AU - Maeurer, Markus

AU - Mwaba, Peter

AU - Kapata, Nathan

AU - Bates, Matthew

AU - Hoelscher, Michael

AU - Zumla, Alimuddin

PY - 2011

Y1 - 2011

N2 - In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and discuss future prospects for TB diagnostics. Current technologies for the detection of drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the ‘holy grail’ diagnostic for TB must fulfil all technical specifications for a good point-of-care test, screen for drug resistance concurrently and be adaptable to the various health system levels and to countries with diverse economic status and TB burden.

AB - In this review, we describe the phenotypic and genotypic methods currently available for the diagnosis of TB and drug-resistant forms of Mycobacterium tuberculosis and discuss future prospects for TB diagnostics. Current technologies for the detection of drug resistant M. tuberculosis vary greatly in terms of turnaround time, cost and complexity. Ultimately, the ‘holy grail’ diagnostic for TB must fulfil all technical specifications for a good point-of-care test, screen for drug resistance concurrently and be adaptable to the various health system levels and to countries with diverse economic status and TB burden.

U2 - 10.1097/MCP.0b013e3283452346

DO - 10.1097/MCP.0b013e3283452346

M3 - Literature review

SN - 1070-5287

VL - 17

SP - 134

EP - 141

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

IS - 3

ER -